statementSaid on 2026-11-11
Simcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
先聲藥業選擇了一條國際合作路線,與德國Vivoryon合作在中國開發SIM0408,靶向神經毒性澱粉樣蛋白N3pE(pGlu-Aβ),已獲CDE批准進入臨床。